Icatibant Zentiva Pharma Uk (Icatibant)

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and additional doses may be given if needed under medical supervision.

Safety data for icatibant in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing it to pregnant or breastfeeding individuals. The decision is made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates replace a missing protein, and newer monoclonal antibodies target different pathways. Icatibant offers rapid subcutaneous administration and works directly at the receptor level, making it useful for patients who prefer self‑injection and need quick symptom relief.

Icatibant should be stored refrigerated between 2 °C and 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant is given as a subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after proper instruction. The site should be rotated for repeated administrations to minimize local irritation.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, marked hypotension, and paradoxical worsening of angioedema despite treatment. Patients should be monitored closely after the first dose, and any signs of severe allergic reaction or sudden blood pressure drop require immediate medical attention.

Icatibant is contraindicated in individuals with a known hypersensitivity to the drug or any of its excipients. Patients taking ACE inhibitors, neprilysin inhibitors, or estrogen‑containing therapies should discuss potential risks with their physician, as these medications may increase the likelihood of angioedema.